Drug Trial Radar · NCT04994132
A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma
Last checked: Nov 19, 2026Latest source record: Jul 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
113
Actual
Start
Sep 14, 2021
Primary completion
Jun 30, 2026
Study completion Jul 1, 2027
Sponsor
- Lead sponsor
- Children's Oncology GroupResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Aug 6, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase III trial compares the safety and effect of adding vinorelbine to vincristine, dactinomycin, and cyclophosphamide (VAC) for the treatment of patients with high risk rhabdomyosarcoma (RMS). High risk refers to cancer that is likely to recur (come back) after treatment or spread to other parts of the body. This study will also examine if adding maintenance therapy after VAC therapy, with or without vinorelbine, will help get rid of the cancer and/or lower the chance that the cancer comes back. Vinorelbine and vincristine are in a class of medications called vinca alkaloids. They work by stopping cancer cells from growing and dividing and may kill them. Dactinomycin is a type of antibiotic that is only used in cancer chemotherapy. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill cancer cells. It may also lower the body's immune response. Vinorelbine, vincristine, dactinomycin and cyclophosphamide are chemotherapy medications that work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may have the potential to eliminate rhabdomyosarcoma for a long time or for the rest of patient's life.
Conditions
- Alveolar Rhabdomyosarcoma
- Botryoid-Type Embryonal Rhabdomyosarcoma
- Embryonal Rhabdomyosarcoma
- Metastatic Embryonal Rhabdomyosarcoma
- Metastatic Rhabdomyosarcoma
- Solid Alveolar Rhabdomyosarcoma
- Spindle Cell Rhabdomyosarcoma
- Spindle Cell/Sclerosing Rhabdomyosarcoma
Interventions
Biospecimen CollectionProcedure
Undergo blood sample collection
Bone Marrow AspirationProcedure
Undergo bone marrow aspiration
Bone Marrow BiopsyProcedure
Undergo bone marrow biopsy
Bone ScanProcedure
Undergo bone scan
Computed TomographyProcedure
Undergo CT
CyclophosphamideDrug
Given IV or PO
DactinomycinBiological
Given IV
Magnetic Resonance ImagingProcedure
Undergo MRI
Positron Emission TomographyProcedure
Undergo PET
Radiation TherapyRadiation
Undergo radiation therapy
Vincristine SulfateDrug
Given IV
Vinorelbine TartrateDrug
Given IV
X-Ray ImagingProcedure
Undergo x-ray imaging
Primary outcomes
What the sponsor says the trial is designed to measure.
- Event-free survival (EFS)Time frame: Time from randomization to an event defined as disease relapse/progression, second malignancy, or death, whichever occurs first, assessed up to 5 years from study enrollment
Locations
250 sites in 5 countries. Site status is shown where the registry gives one.
Children's Hospital of Alabama
Birmingham, Alabama
USA Health Strada Patient Care Center
Mobile, Alabama
Providence Alaska Medical Center
Anchorage, Alaska
Kingman Regional Medical Center
Kingman, Arizona
Banner Children's at Desert
Mesa, Arizona
Phoenix Childrens Hospital
Phoenix, Arizona
Banner University Medical Center - Tucson
Tucson, Arizona
Arkansas Children's Hospital
Little Rock, Arkansas
Kaiser Permanente-Anaheim
Anaheim, California
PCR Oncology
Arroyo Grande, California
Kaiser Permanente-Bellflower
Bellflower, California
Kaiser Permanente Downey Medical Center
Downey, California
City of Hope Comprehensive Cancer Center
Duarte, California
Kaiser Permanente-Fontana
Fontana, California
Loma Linda University Medical Center
Loma Linda, California
Miller Children's and Women's Hospital Long Beach
Long Beach, California
Children's Hospital Los Angeles
Los Angeles, California
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California
Cedars-Sinai Medical Center
Los Angeles, California
Mattel Children's Hospital UCLA
Los Angeles, California
Valley Children's Hospital
Madera, California
UCSF Benioff Children's Hospital Oakland
Oakland, California
Kaiser Permanente-Oakland
Oakland, California
Children's Hospital of Orange County
Orange, California
Lucile Packard Children's Hospital Stanford University
Palo Alto, California
University of California Davis Comprehensive Cancer Center
Sacramento, California
Kaiser Permanente-San Diego Zion
San Diego, California
Rady Children's Hospital - San Diego
San Diego, California
Naval Medical Center -San Diego
San Diego, California
UCSF Medical Center-Mission Bay
San Francisco, California
Children's Hospital Colorado
Aurora, Colorado
Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
Denver, Colorado
Connecticut Children's Medical Center
Hartford, Connecticut
Smilow Cancer Center/Yale-New Haven Hospital
New Haven, Connecticut
Yale University
New Haven, Connecticut
Alfred I duPont Hospital for Children
Wilmington, Delaware
MedStar Georgetown University Hospital
Washington D.C., District of Columbia
Children's National Medical Center
Washington D.C., District of Columbia
Broward Health Medical Center
Fort Lauderdale, Florida
Golisano Children's Hospital of Southwest Florida
Fort Myers, Florida
Showing 40 of 250 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.